Q-omics provides the consensus-scored SNAPC5 profile across patient tissues and cancer cell-line models. SNAPC5 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SNAPC5 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, SNAPC5 RNA expression shows 19,252 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and HNSC as cancer lineages where SNAPC5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNAPC5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNAPC5 survival associations across molecular data types. SNAPC5 RNA expression shows survival associations in the most cancer types (26), followed by mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNAPC5 RNA expression–survival associations across cancer types. High SNAPC5 expression shows unfavorable associations in UVM, COAD, LGG, UCS and KICH, but favorable associations in SARC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for SNAPC5 RNA expression.
This table summarizes SNAPC5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SNAPC5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNAPC5 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, STAD and COAD. The HNSC box plot shows higher SNAPC5 RNA expression in tumor versus normal tissue (log2 FC = +0.890, t-test p < 0.001).
This table shows molecular features associated with SNAPC5 in patient tissues and cancer cell lines. In patient samples, SNAPC5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SNAPC5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
